Syntara says clearer guidance from regulators gives it a more straightforward path to test its lead blood-disorder drug, while it also has shots on goal in Parkinson’s-related brain inflammation and surgical scarring. The catch is it still needs more funding and faces fast-moving competition, so the next partner talks and trial updates matter.Read more

AU$0.1

74.3% undervalued

AnalystConsensusTarget's

Fair Value

Profit Margin

35.73%

Future PE

233.18x

Price in 2029

AU$0.13

Syntara

Phase IIb Myelofibrosis Catalyst Will Drive Long-Term Upside Potential

Syntara is lining up an FDA-backed next trial for its lead drug in a rare blood disease, and big pharma deal activity in the space could make it an attractive partner if the data holds up. The catch is that several programs are still early and the company needs fresh funding to move forward, so the payoff depends on strong trial results and a clear path to finance them.Read more

AU$0.15

82.0% undervalued

AnalystHighTarget's

Fair Value

Profit Margin

28.1%

Future PE

106.31x

Price in 2029

AU$0.18

Trending Discussion

No trending discussion available.

Snowflake Analysis

Flawless balance sheet with moderate risk.

5 Risks

0 Rewards

View Full Analysis

Syntara Limited Key Details

Last Reported Earnings

Dec 31, 2025

Next Reporting Earnings

n/a

: -0.0067
: -51.45%
: -175.46%
: 0%

View Full Analysis

About SNT

Founded: 1998
Employees: n/a
CEO: Gary Phillips
WebsiteView website: syntaratx.com.au

Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and is in Phase 1c/2 studies for patients with myelodysplastic syndrome. The company also develops topical pan-LOX inhibitors with SNT-9465, which is in a Phase 1a/b study for hypertrophic scars; SNT-6302 for keloid scars; and SNT-4728 to treat sleep disorders and slow progression of neurodegenerative diseases by reducing neuroinflammation. In addition, it develops other drug candidates that target fibrotic and inflammatory diseases, including kidney fibrosis, MASH, pulmonary fibrosis, and cardiac fibrosis. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.